Dupixent Endorsed in EU for Treating Eosinophilic Esophagitis in Children
Friday, 20 September 2024, 21:10
Understanding Eosinophilic Esophagitis
Eosinophilic esophagitis is a chronic immune system disease that affects the esophagus. Symptoms can include difficulty swallowing, pain, and food getting stuck.
Regeneron and Sanofi's Breakthrough
- Dupixent is the first treatment specifically endorsed for eosinophilic esophagitis in children as young as one year old.
- This therapy works by blocking interleukin-4 and interleukin-13 signaling pathways, which are important in the inflammation process.
- The endorsement from the European Medicines Agency (EMA) is a significant step in improving care for affected children.
Importance of Early Diagnosis and Treatment
Early diagnosis of eosinophilic esophagitis is crucial. Symptoms may be easily misdiagnosed, leading to delay in treatment. The availability of Dupixent provides a much needed treatment option to manage symptoms effectively and improve the quality of life.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.